Terbinafine. An update of its use in superficial mycoses

Drugs

Volumn 58, Issue 1, 1999, Pages 179-202

  McClellan, Karen J ^a   Wiseman, Lynda R ^a   Markham, Anthony ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Mycoses; Nail disorders; Pharmacodynamics; Pharmacoeconomics; Pharmacokinetics; Skin disorders; Terbinafine; Therapeutic use

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; BIFONAZOLE; CICLOPIROX; CIMETIDINE; CLOTRIMAZOLE; CYCLOSPORIN; DIGOXIN; GRISEOFULVIN; HISTAMINE H2 RECEPTOR ANTAGONIST; INSULIN; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; MIDAZOLAM; NAFTIFINE; ORAL CONTRACEPTIVE AGENT; OXICONAZOLE; RIFAMPICIN; TERBINAFINE; THEOPHYLLINE; TRIAZOLAM; WARFARIN;

ABDOMINAL PAIN; BLOOD TOXICITY; CANDIDA ALBICANS; CANDIDIASIS; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DERMATOPHYTE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG MECHANISM; EDEMA; FUNGICIDAL ACTIVITY; HEPATITIS; HUMAN; MOULD; MUSCULOSKELETAL DISEASE; MYCOSIS; NAUSEA; ONYCHOMYCOSIS; ORAL DRUG ADMINISTRATION; RESPIRATORY TRACT DISEASE; REVIEW; SKIN TOXICITY; TASTE DISORDER; TINEA CORPORIS; TINEA CRURIS; TINEA PEDIS; TINEA VERSICOLOR; TOPICAL DRUG ADMINISTRATION;

EID: 0032791888     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958010-00018     Document Type: Review

References (145)

1. 1. Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992 Feb; 43: 259-84
2. 2. Roberts DT. Oral terbinafine (Lamisil®) in the treatment of fungal infections of the skin and nails. Dermatology 1997; 194 Suppl. 1: 37-9
3. 3. Rashid A. New mechanisms of action with fungicidal antifungals. Br J Dermatol 1996 Jun; 134 Suppl. 46: 1-6
4. 4. Petranyi G, Meingassner JG, Mieth H. Antifungal activity of the allylamine derivative terbinafine in vitro. Antimicrob Agents Chemother 1987 Sep; 31 (9): 1365-8
5. 5. Shadomy S, Espinel-Ingroff A, Gebhart RJ. In vitro studies with SF s6-327, a new orally active allylamine derivative. J Med Vet Mycol 1985; 23: 125-32
6. 6. Clayton YM. Relevance of broad-spectrum and fungicidal activity of antifungals in the treatment of dermatomycoses. Br J Dermatol 1994 Apr; 130 Suppl. 43: 7-8
7. 7. Hazen KC. Fungicidal versus fungistatic activity of terbinafine and itraconazole: an in vitro comparison. J Am Acad Dermatol 1998; 38: S37-41
8. 8. Barchiesi F, Falconi di Francesco L, Scalise G. In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility tu azoles. Antimicrob Agents Chemother 1997; 41 (8): 1812-4
9. 9. Leeming JP, Sansom JE, Burton JL. Susceptibility of Malassezia furfur subgroups to terbinafine. Br J Dermatol 1997; 137: 764-7
10. 10. Rex JH, Pfaller MA, Rinaldi MG, et al. Antifungal susceptibility testing. Clin Microbiol Rev 1993 Oct; 6 (4): 367-81
11. 11. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Proposed standard. Document M27-P, 1992; USA
12. 12. Kovarik JM, Kirkesseli S, Humbert H, et al. Dose-proportional pharmacokinetics of terbinafine and its N-demethylated metabolite in healthy volunteers. Br J Dermatol 1992 Feb; 126 Suppl. 39: 8-13
13. 13. Nejjam F, Zagula M, Cabiac MD, et al. Pilot study of terbinafine in children suffering from tinea capitis: evaluation of efficacy, safety and pharmacokinetics. Br J Dermatol 1995 Jan; 132: 98-105
14. 14. Nedelman J, Cramer JA, Robbins B, et al. The effect of food on the pharmacokinetics of multiple-dose terbinafine in young and elderly healthy subjects. Biopharm Drug Dispos 1997 Mar; 18: 127-38
15. 15. Villars V, Jones TC. Present status of the efficacy and tolerability of terbinafine (Lamisil) used systemically in the treatment of dermatomycoses of skin and nails. J Dermatol Treat 1990; 1 Suppl. 2: 33-8
16. 16. Jensen JC. Pharmacokinetics of Lamisil in humans. J Dermatol Treat 1990 Suppl. 2: 15-8
17. 17. Stephen A, Czok R, Male O. Terbinafine: initial clinical results. In: Fromtling RA, editor. Recent trends in the discovery, development and evaluation of antifungal agents. Barcelona: J.R. Prous Science Publishers S.A., 1987: 511-20
18. 18. Faergemann J, Zehender H, Denouël J, et al. Levels of terbinafine in plasma, stratum comeum, dermis-epidermis (without stratum comeum), sebum, hair and nails during and after 250mg terbinafine orally once per day for four weeks. Acta Derm Venereol 1993 Aug; 73: 305-9
19. 19. Faergemann J, Zehender H, Jones T, et al. Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and ecerine sweat. Acta Derm Venereol 1991; 71: 322-6
20. 20. Schatz F, Bräutigam M, Dobrowolski E, et al. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol 1995 Sep; 20: 377-83
21. 21. Ryder NS, Frank I. Interaction of terbinafine with human serum and serum proteins. J Med Vet Mycol 1992; 30 (6): 451-60
22. 22. Schuster I. The interaction of representative members from two classes of antimycotics - the azoles and the allylamines - with cytochromes P-450 in steroidogenic tissues and liver. Xenobiotica 1985; 15: 529-46
23. 23. Wahlländer A, Paumganner G. Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. Eur J Clin Pharmacol 1989; 37: 279-83
24. 24. Zehender H, Cabiac MD, Denouël J, et al. Elimination kinetics of terbinafine from human plasma and tissues following multiple-dose administration, and comparison with 3 main metabolites. Drug Invest 1994 Oct; 8: 203-10
25. 25. Jensen JC. Clinical pharmacokinetics of terbinafine (Lamisil). Clin Exp Dermatol 1989; 14: 110-3
26. 26. Ganzinger U, Stephen A, Hitzenberger G, et al. SF 86-327: evaluation of toxicity in laboratory animals, tolerance and pharmacokinetics after oral application to man. In: Spitzy KH, Karrer K, editors. Proceedings of the 13th International Congress of Chemotherapy; 1992 Aug 28-Sep 2; Vienna, Pt 116. Neulenbach, Austria: H. Egermann Publishers, 1983; 52-8
27. 27. Kovarik JM, Mueller EA, Zehender H, et al. Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites. Antimicrob Agents Chemother 1995 Dec; 39: 2738-41
28. 28. Trépanier EF, Nafziger AN, Amsden GW. Effect of terbinafine on theophylline pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother 1998; 42: 695-7
29. 29. Hall M, Monka C, Krupp P, et al. Safety of oral terbinafine: results of a postmarketing surveillance study in 25 884 patients. Arch Dermatol 1997 Oct; 133: 1213-9
30. 30. Guerret M, Francheteau P, Hubert M. Evaluation of effects of terbinafine on single oral dose pharmacokinetics and anticoagulant actions of warfarin in healthy volunteers. Pharmacotherapy 1997; 17 (4): 767-73
31. 31. Tarral A, Francheteau P, Guerret M. Effects of terbinafine on the pharmacokinetics of digoxin in healthy volunteers. Pharmacotherapy 1997; 17 (4): 791-5
32. 32. Varhe A, Olkkola KT, Neuvonen PJ. Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br J Clin Pharmacol 1996 Apr; 41: 319-23
33. 33. Ahonen J, Olkkola KT, Neuvonen PJ. Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol 1995 Sep; 40: 270-2
34. 34. Robbins B, Chang C-T, Cramer JA, et al. Safe coadministration of terbinafine and terfenadine: a placebo-controlled crossover study of pharmacokinetic and pharmacodynamic interactions in healthy volunteers. Clin Pharmacol Ther 1996 Mar; 59: 275-83
35. 35. Jensen P, Lehne G, Fauchald P, et al. Effect of oral terbinafine treatment on cyclosporin pharmacokinetics in organ transplant recipients with dermatophyte nail infection. Acta Derm Venereol 1996 Jul; 76: 280-1
36. 36. Long CC, Hill SA, Thomas RC, et al. Effect of terbinafine on the pharmacokinetics of cyclosporin in humans. J Invest Dermatol 1994 May, 102: 740-3
37. 37. Malaty LI, Kuper JJ. Drug interactions of HIV protease inhibitors. Drug Saf 1999 Feb; 20 (2): 147-69
38. 38. Hill S, Thomas R, Smith SG, et al. An investigation of the pharmacokinetics of topical terbinafine (Lamisil Rm) 1% cream. Br J Dermatol 1992 Oct; 127: 396-400
39. 39. Dykes PJ, Thomas R, Lever L, et al. Pharmacokinetics of topically applied terbinafine: results from studies in healthy volunteer subjects and patients with pityriasis versicolor. J Dermatol Treat 1990; 1 Suppl. 2: 19-21
40. 40. Denning DW, Evans EGV, Kibbler CC, et al. Fungal nail disease: a guide to good practice (report of a Working Group of the British Society for Medical Mycology). BMJ 1995 Nov 11; 311: 1277-81
41. 41. Elewski BE. Large-stale epidemiological study of the causal agents of onychomycosis: mycological findings from the multicenter onychomycosis study of terbinafine. Arch Dermatol 1997; 133: 1317-8
42. 42. Ellis DH, Watson AB, Marley JE, et al. Non-dermatophytes in onychomycosis of the toenails. Br J Dermatol 1997; 136: 490-3
43. 43. Roberts DT. The clinical efficacy of terbinafine in the treatment of fungal infections of nails. Rev Contemp Pharmacother 1997; 8: 299-312
44. 44. Haneke E. Tausch I, Bräutigam M, et al. Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. J Am Acad Dermatol 1995 Jan; 32: 72-7
45. 45. Van Der Schroeff JG, Cirkel PKS, Crijns MB, et al. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol 1992 Feb; 126 Suppl. 39: 36-9
46. 46. Drake LA, Shear NH, Arlette JP, et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol 1997; 37: 740-5
47. 47. Watson A, Marley J, Ellis D, et al. Terbinafine in onychomycosis of the toenail: a novel treatment protocol. J Am Acad Dermatol 1995 Nov; 33 (Pt I): 775-9
48. 48. Faergemann J, Anderson C, Hersle K, et al. Double-blind, parallel-group comparison of terbinafine und griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol 1995 May; 32 (Pt 1): 750-3
49. 49. Hofmann H, Bräutigam M, Weidinger G, et al. Treatment of toenail onychomycosis: a randomized, double-blind study with terbinafine and griseofulvin. Arch Dermatol 1995 Aug; 131: 919-22
50. 50. Bräutigam M, Nolting S, Schopf RE, et al. Randomised double-blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. BMJ 1995 Oct 7; 311: 919-22
51. 51. De Backer M, De Vroey C, Lesaffre E, et al. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. J Am Acad Dermatol 1998; 38 (5 Pt 3): S57-63
52. 52. Degreef H, De Doncker P. Joosen H, et al. Randomized, double-blind trial on the efficacy and tolerability of itracona/ole 200 mg compared with terbinafine 250mg in the treatment of toenail onychomycosis. Australas J Dermatol 1997 Jun; 38 (Abstracts of the 19th World Congress of Dermatology) Suppl. 2: 92-3
53. 53. Honeyman JF, Talarico FS, Arruda LHF, et al. Itraconazole versus terbinafine (LAMISIL): which is better for the treatment of onychomycosis? J Eur Acad Dermatol Venereol 1997; 9: 215-21
54. 54. Evans EGV, Sigurgeirsson B, et al. for the LION study group. Double-blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. BMJ 1999; 318: 1031-5
55. 55. Havu V, Heikkilä H, Stubb S, et al. A study to compare the efficacy of Lamisil® (terbinafine) and Diflucan® (fluconazole) in patients with onychomychosis [abstract]. J Eur Acad Dermatol Venereol 1996 Oct; 7 Suppl. 2: 154
56. 56. Havu V, Heikkilä H, Kuokkanen K, et al. A double-blind, randomised study to compare the efficacy and safety of terbinafine (Lamisil®) with fluconazole (Diflucan®) in the treatment of onychomycosis. Novartis 1999. (Data on file)
57. 57. Alpsoy E, Yilmaz E, Basaran E. Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach. J Dermatol 1996; 23 (4): 259-62
58. 58. Tosti A, Piraceini BM, Stinchi C, et al. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 1996 Apr; 34: 595-600
59. 59. Nolting S, Brautigam M, Weidinger G. Terbinafine in onychomycosis with involvement by non-dermatophytic fungi. Br J Dermatol 1994 Apr: 130 Suppl. 43: 16-21
60. 60. Segal R, Kritzman A, Cividalli L, et al. Treatment of Candida nail infection with terbinafine. J Am Acad Dermatol 1996 Dec; 35: 958-61
61. 61. Roberts DT, Richardson MD, Dwyer PK, et al. Terbinafine in chronic paronychia and candida onychomycosis. J Dermatol Treat 1992; 3 Suppl. 1: 39-42
62. 62. Tosti A, Piraceini BM, Stinchi C, et al, Onychomycosis due to Scopulariopsis brevicaulis: clinical features and reponse to systemic antifungals. Br J Dermatol 1996 Nov; 135: 799-802
63. 63. Nandwani R, Parnell A, Youle M, et al. Use of terbinafine in HIV-positive subjects: pilot studies in onychomycosis and oral candidiasis. Br J Dermatol 1996 Jun; 134 Suppl. 46: 22-4
64. 64. Herranz P, García J, De Lucas R, et al. Toenail onychomycosis in patients with acquired immune deficiency syndrome: treatment with terbinafine. Br J Dermatol 1997; 137: 577-80
65. 65. Lee KH, Kim YS, Kim MS, et al. Study of the efficacy and tolerability of oral terbinafine in the treatment of onychomycosis in renal transplant patients [abstract]. Transplant Proc 1996 Jun; 28: 1488-9
66. 66. Marchese LM, Cucé LC, Chocair PR, et al. Efficacy and safety of terbinafine by oral route in the treatment of onychomycosis in renal transplanted patients [abstract]. J Eur Acad Dermatol Venereol 1996 Oct; 7 Suppl. 2: S95
67. 67. Abdel-Rahman SM, Nahata MC. Treatment of tinea capitis. Ann Pharmacother 1997 Mar, 31: 338-48
68. 68. Elewski BE. Treatment of tinea capitis: should terbinafine replace griseofulvin? J Dermatol Treat 1998; 9 Suppl. 1: S9-11
69. 69. Frieden U, Howard R. Tinea capitis: epidemiology, diagnosis, treatment, and control. J Am Acad Dermatol 1994 Sep; 31 (Pt 2): S42-46
70. 70. Haroon TS, Hussain I. Mahmood A, et al. An open clinical pilot study of the efficacy and safety of oral terbinafine in dry non-inflammatory tinea capitis. Br J Dermatol 1992 Feb; 126 Suppl. 39: 47-50
71. 71. Haroon TS, Hussain I, Aman S, et al. A randomized double-blind comparative study of terbinafine and griscofulvin in tinea capitis. J Dermatol Treat 1995 Sep; 6: 167-9
72. 72. Memisoglu HR, Erboz S, Akkaya S, et al. Comparison of efficacy and tolerability of 4 weeks of terbinafine therapy with 8 weeks of griseofulvin therapy in children with tinea capitis. Australas J Dermatol 1997 Jun; 38 (Abstracts of the 19th World Congress of Dermatology) Suppl. 2: 97
73. 73. Haroon TS, Hussain I, Aman S, et al. A randomized double-blind comparative study of terbinafine for 1, 2 and 4 weeks in tinea capitis. Br J Dermatol 1996 Jul; 135: 86-8
74. 74. Baudraz-Rosselet F, Monod M, Jaccoud S, et al. Efficacy of terbinafine treatment of tinea capitis in children varies according to the dermatophyte species [letter]. Br J Dermatol 1996 Dec; 135: 1011-2
75. 75. Rademaker M, Havill S. Griseofulvin and terbinafine in the treatment of tinea capitis in children. N Z Med J 1998 Feb 27; 111: 55-7
76. 76. Bruckbauer HR, Hofmann H. Systemic antifungal treatment of children with terbinafine. Dermatology 1997; 195: 134-6
77. 77. Piérard GE, Arrese JE, Piérard-Franchimont C. Treatment and prophylaxis of tinea infections. Drugs 1996 Aug; 52: 209-24
78. 78. White JE, Perkins PJ, Evans EG. Successful 2-week treatment with terbinafine (Lamisil) for moccasin tinea pedis and tinea manuum. Br J Dermatol 1991 Sep; 125: 260-2
79. 79. Talarico-Filho S. Double-blind comparative study on terbinafine 250 mg once a day and griseofulvin 500 mg twice a day during 6 weeks in patients with tinea pedis mocassin type [abstract]. International Meeting Skin Therapy Update '94; 1994 Oct 14-17; Crete, 281
80. 80. De Keyser P, De Backer M, Massart DL, et al. Two-week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double-blind, multicentre study. Br J Dermatol 1994; 130 Suppl. 43: 22-5
81. 81. Hay RJ, McGregor JM, White J, et al. A comparison of 2 weeks of terbinafine 250 mg/day with 4 weeks of itraconazole 100 mg/day in plantar-type tinea pedis. Br J Dermatol 1995 Apr; 132: 604-8
82. 82. Kim K-H, Choi JS, Park ES, et al. A multicenter, double blind, comparative study of the efficacy and safety of terbinafine 250 mg/day for 2 weeks versus itraconazole 100 mg/day for 4 weeks in the treatment of patients with tinea pedis [abstract]. International Conference on Skin Therapy Update 1995; Oct 20; Singapore, 31
83. 83. Tausch I, Decroix J, Gwiezdzinski Z, et al. Short term itraconazole versus terbinafine in the treatment of tinea pedis or manus. Int J Dermatol 1998 Feb; 37: 140-2
84. 84. Gupta A, De Doncker P, Heremans A, et al, Itraconazole in tinea pedis: a dose of 400 mg/day given for 1 week is more effective than 100 or 200 mg/day given for 2-4 weeks [abstract]. J Eur Acad Dermatol Venereol 1995 Oct; 5 Suppl. 1: S173
85. 85. Decroix J. Tinea pedis (mocassin-type) treated with itracon azole. Int J Dermatol 1995 Feb; 34 (2): 122-4
86. 86. Barnetson RStC, Marley J, Bullen M, et al. Comparison of one week of oral terbinafine (250 mg/day) with four weeks of treatment with clotrimazole 1% cream in interdigital tinea pedis. Br J Dermatol 1998; 139: 675-8
87. 87. Voravutinon V. Oral treatment of tinea corporis and tinea cruris with terbinafine and griseofulvin: a randomized double blind comparative study. J Med Assoc Thai 1993 Jul; 76: 388-93
88. 88. Villars V, Jones TC. Clinical efficacy and tolerability of terbinafine (Lamisil) - a new topical and systemic fungicidal drug for treatment of dermatomycoses. Clin Exp Dermatol 1989; 14: 124-7
89. 89. Jung EG, Haas PJ, Brautigam M, et al. Systemic treatment of skin candidosis: a randomized comparison of terbinafine and ketoconazole. Mycoses 1994 Sep-Oct; 37: 361-5
90. 90. Budimulja U, Kuswadji K, Bramono S, et al. A double-blind, randomized, stratified controlled study of the treatment of tinea imbricata with oral terbinafine or itraconazole. Br J Dermatol 1994 Apr; 130 Suppl. 43: 29-31
91. 91. Berman B, Ellis C, Leyden J, et al. Efficacy of a 1-week, twice-daily regimen of terbinafine 1% cream in the treatment of interdigital tinea pedis. Results of placebo-controlled, double-blind, multicenter trials. J Am Acad Dermatol 1992 Jun; 26: 956-60
92. 92. Savin R, Atton AV, Bergstresser PR, et al. Efficacy of terbinafine 1% cream in the treatment of moccasin-type tinea pedis: results of placebo-controlled multicenter trials. J Am Acad Dermatol 1994 Apr; 30: 663-7
93. 93. Cordero C, de la Rosa I, Espinosa Z, et al. Short term therapy of tinea cruris/corporis with topical terbinafine. J Dermatol Treat 1992; 3 Suppl. 1: 23-4
94. 94. Evans EGV, Shah JM, Joshipura RC. One-week treatment of tinea corporis and tinea cruris with terbinafine (Lamisil) 1% cream: a placebo-controlled study. J Dermatol Treat 1992 Dec; 3: 181-4
95. 95. van Heerden JS, Vismer HF. Tinea corporis/cruris: new treatment options. Dermatology 1997; 194 Suppl. 1: 14-8
96. 96. Sanchez Carazo JL, Fuente C, Oliver V, et al. Estudio comparativo de terbinafina vs. bifonazol crema 1% en aplicación única diaria en tiña pedis. Actas Dermo Sifiliogr 1994; 85 (5): 388-94
97. 97. Wahid Z, Butt J, Nishtar R. Multicentre double-blind study of efficacy and safety of terbinafine 1% cream compared with bifonazole 1% cream in patients with tinea pedis moccasin type. J Dermatol Treat 1997; 8: 225-7
98. 98. Bergstresser PR, Elewski B, Hanifin J, et al. Topical terbinafine and clotrimazole in interdigital linea pedis: a multicenter comparison of cure and relapse rates with 1-and 4-week treatment regimens. J Am Acad Dermatol 1993 Apr; 28: 648-51
99. 99. Evans EGV, Dodman B, Williamson DM, et al. Comparison of terbinafine and clotrimazole in treating tinea pedis. BMJ 1993 Sep 11; 307: 645-7
100. 100. Vermeer BI, Staats CC, van-Houwelingen JC. Terbinafine versus micunazole in patients with tinea pedis [in Dutch]. Ned Tijdschr Geneeskd 1996 Aug 3; 140: 1605-8
101. 101. Ablon G, Rosen T, Spedale J. Comparative efficacy of naftifine, oxiconazole, and terbinafine in short term treatment of tinea pedis. Int J Dermatol 1996 Aug; 35: 591-3
102. 102. Elewski B, Bergstresser PR, Hanifin J, et al. Long term outcome of patients with interdigital tinea pedis treated with terbinafine or clotrimazole. J Am Acad Dermatol 1995 Feb; 32 (Pt 1); 290-2
103. 103. Bakos L, Brito AC, Castro LCM, et al. Open clinical study of the efficacy and safety of terbinafine cream 1% in children with tinea corporis and tinea cruris. Pediatr Infect Dis J 1997; 16: 545-8
104. 104. Faergemann J, Hersle K, Nordin P. Pityriasis versicoloc: clinical experience with Lamisil® cream and Lamisil® DermGel. Dermatology 1997; 194 Suppl. 1: 19-21
105. 105. Vermeer BJ, Staats CCG. The efficacy of a topical application of terbinafine 1% solution in subjects with pityriasis versicolor: a placebo-controlled study. Dermatology 1997; 194 Suppl. 1: 22-4
106. 106. Faergemann J, Jones TC, Hettler O, et al. Pityrosporum ovale (Malassezia furfur) as the causative agent of seborrhocic dermatitis: new treatment options. Br J Dermatol 1996 Jun; 134 Suppl. 46: 12-5
107. 107. Novartis Pharma AG. Lamisil tablets: basic prescribing information. Basel, Switzerland, 1997. (Data on file)
108. 108. Lowe G, Green C, Jennings P. Hepatitis associated with terbinafine treatment [letter]. BMJ 1993 Jan 23; 306: 248
109. 109. Boldewijn OY, Qttervanger JP, Mostart CMJA, et al. Hepatitis attributed to the use of terbinafine [in Dutch]. Ned Tijdschr Geneeskd 1996 Mar 23; 140: 669-72
110. 110. Van't Wout JW, Herrmann WA, de Vries RA, et al. Terbinafinc-associated hepatic injury. J Hepatol 1994 Jul; 21: 115-7
111. 111. Vantaux P, Grasset D, Nougue J, et al. Hépatite aiguë en rapport avec la prise de terbinafine. Gastroenterol Clin Biol 1996 May; 20: 402-3
112. 112. Mallat A, Zafrani ES, Metreau JM, et al. Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts. Dig Dis Sci 1997 Jul; 42 (7): 1486-8
113. 113. Lazaros GA, Papatheodoridis GV, Delladetsima JK, et al. Terbinafine-induced cholestatic liver disease. J Hepatol 1996 Jun; 24: 753-6
114. 114. Fernandes NF, Geller SA, Fong T-L. Terbinafine hepatoxicity: case report and review of the literature. Am J Gastroenterol 1998; 93 (3): 459-60
115. 115. Dwyer CM, White MI, Sinclair TS. Cholestatic jaundice due to terbinafine [letter]. Br J Dermatol 1997; 136: 976-7
116. 116. Rzany B, Mockenhaupt M, Gehring W, et al. Stevens-Johnson syndrome after terbinafine therapy [letter]. J Am Acad Dermatol 1994 Mar; 30: 509
117. 117. Todd P, Halpern S, Munro DD. Oral terbinafine and erythema multiforme. Clin Exp Dermatol 1995 May; 20: 247-8
118. 118. Tramaloni S, Castanet J. Chichmanian RM, et al. Erythema multiforme following therapy with terbinafine [in French]. Therapie 1995 Nov-Dec; 50: 594-5
119. 119. Carstens J, Wendelboe P, Søgaard H, et al. Toxic epidermal necrolysis und erythema multiforme following therapy with terbinafine. Acta Derm Venereol 1994 Sep; 74: 391-2
120. 120. White SI, Bowen-Jones D. Toxic epidermal necrolysis induced by terbinafine in a patient on long term anti-epileptics. Br J Dermatol 1996 Jan; 134: 188-9
121. 121. Kovacs MJ, Alshammari S, Guenther L, et al. Neutropenia and pancytopenia associated with oral terbinafine. J Am Acad Dermatol 1994 Nov; 31 (Pt 1): 806
122. 122. Gupta AK, Soori GS, Del Rosso JQ, et al. Severe neutropenia associated with oral terbinafine therapy. J Am Acad Dermatol 1998; 38 (5): 765-7
123. 123. Barete S, Bissuel F, Longuet P, et al. Agranulocytose au cours d'un traitement par terbinafine. Rev Med Interne 1997; 18 (3): 258-9
124. 124. Terbinafine - haematological reactions. In: Bulletin from SADRAC:, 1995: Apr
125. 125. Arikian SR, Einarson TR, Kobelt-Nguyen G, et al. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. Br J Dermatol 1994 Apr; 130 Suppl. 43: 35-4
126. 126. Einarson TR, Arikian SR, Shear NH. Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective. Br J Dermatol 1994 Apr: 130 Suppl. 43: 32-4
127. 127. Kobelt-Nguyen G, van Assche D. Nagelmykosen der Fingerund Zehennägel: pharmakoökonomische analyse für die orale behandlung in Deutschland. Z Allgemeinmed 1994 Sep 5; 70: 683-5
128. 128. Bergman W, Rutten FFH. Orale behandeling van onychomycose van de teenagels; vergelijking van kosteneffectiviteit van griseofulvine, itraconazol, ketoconazol en terbinafine. Ned Tijdschr Geneeskd 1994 Nov 19; 138: 2346-50
129. 129. Marchetti A, Tak-Piech C, McGhan WF, et al. Pharmacoeconomics analysis of oral therapies for onychomycosis: a US model. Clin Ther 1996 Jul-Aug; 18: 757-77
130. 130. Bootman JL. Cost-effectiveness of two new treatments for onychomycosis: an analysis of two comparative clinical trials. J Am Acad Dermatol 1998; 38: S69-72
131. 131. Goodfield MJD, Bosanquet N, Evans EGV, et al. Cost effective clinical management of onychomycosis. Br J Med Econ 1994; 7: 15-23
132. 132. Gupta AK. Pharmacocconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails: a US analysis. Pharmacoeconomics 1998 Feb; 13: 243-56
133. 133. Van Dootslaer EKA, Tormans G, Gupta AK, et al. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany. Dermatology 1996; 193: 239-44
134. 134. Einarson TR, Arikian SR, Shear NH. Pharmacoeconomic analysis of oral drugs in treatment of tinea infections. J Res Pharm Econ 1995; 6 (3): 15-37
135. 135. Chren M-M, Landefeld CS. A cost analysis of topical drug regimens for dermatophyte infections. JAMA 1994 Dec 28; 272: 1922-5
136. 136. Shear NH, Einarson TR, Arikian SR, et al. Pharmacoeconomic analysis of topical treatments for tinea infections. Pharmacoeconomics 1995 Mar; 7: 251-67
137. 137. Shear NH, Einarson TR, Arikian SR, et al. Pharmacoeconomic analysis of topical treatments for tinea infections: a comparative analysis in Austria, Germany and Switzerland [in German]. Z Allgemeinmed 1995; 71: 1055-60
138. 138. Novartis Pharma AG. Lamisil cream: summary of product characteristics. Basel, Switzerland, 1995. (Data on file)
139. 139. Novartis Pharma AG. Lamisil DermGel: new proposed summary of product characteristics. Basel, Switzerland, 1998. (Data on file)
140. 140. Novartis Pharma AG. Lamisil solution: summary of product characteristics. Basel, Switzerland, 1996. (Data on file)
141. 141. Novartis Pharma AG. Lamisil spray: summary of product characteristics. Basel, Switzerland, 1996. (Data on file)
142. 142. Hay RJ. Onychomycosis. Agents of choice. Dermatol Clin 1993 Jan; 11: 161-9
143. 143. Odom RB. New therapies for onychomycosis. J Am Acad Dermatol 1996 Sep; 35 (3 Pt 2): S26-30
144. 144. Roberts DT. Oral therapeutic agents in fungal nail disease. J Am Acad Dermatol 1994 Sep; 31 (Pt 2): 78-81
145. 145. Hay RJ. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol 1993 Jul; 29: S50-4